Core Viewpoint - The company has repurchased a total of 549,800 ordinary shares as treasury stock, representing approximately 0.24% of the existing issued share capital as of the announcement date [1] Group 1 - The share repurchase was authorized by shareholders at the annual general meeting held on June 20, 2025 [1] - The total amount involved in the repurchase is approximately HKD 11.07 million, excluding commissions and other expenses [1] - The repurchase took place on the Hong Kong Stock Exchange from November 6, 2025, to the date of the announcement [1]

Core Viewpoint - The company believes its current stock price significantly undervalues its intrinsic value and future growth prospects [1] Summary by Sections - **Stock Buyback Announcement** - The company has repurchased a total of 549,800 ordinary shares as treasury stock from November 6, 2025, to the date of the announcement [1] - The repurchased shares represent approximately 0.24% of the company's total issued shares as of the announcement date [1] - The total amount involved in the buyback is approximately HKD 11.07 million, excluding commissions and other expenses [1]

Core Viewpoint - The company believes its current stock price significantly undervalues its intrinsic value and future growth prospects [1] Group 1: Share Buyback - The company has repurchased a total of 549,800 ordinary shares as treasury stock from November 6, 2025, to the date of the announcement [1] - The repurchased shares represent approximately 0.24% of the company's total issued shares as of the announcement date [1] - The total amount involved in the buyback is approximately HKD 11.07 million, excluding commissions and other expenses [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本 公 司 董 事 會（「董事會」）認 為 本 公 司 目 前 股 價 嚴重低估 本 公 司 的 價 值。憑 藉 對 本 公 司 未 來 發 展 前 景 的 充 分 信 心 及 對 本 公 司 內 在 價 值 的 高 度 認 同，為 持 續 增 強 市 場 對本公司的信心並提升本公司的投資價值，根據本公司股東於2025年6月20日舉行 的股東週年大會上 批 准 授 予 本 公 司 董 事（「董 事」）的股份購回授權，本公司已於2025 年11月6日至本公告日期在香港聯合交易所有限公司購回合共549,800股普通股作 為庫存股。所購回的股份佔本公司於本公告日期的現有已發行股份總數約0.24%。 於本公告日期，購回涉及的 總 金額為 約11.07百萬港元（不包括佣金及其他開支）。 股 東 及 潛 在 投 資 者 應 注 意，本 公 司 進 行 場 ...

Core Viewpoint - The company, Zhenxin Biotechnology-B (02509), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Categories Company Actions - The company will spend HKD 2.9983 million to repurchase 156,400 shares [1] - The buyback price per share ranges from HKD 18.42 to HKD 19.84 [1]

荃信生物-B(02509)发布公告，该公司于2025年11月10日斥资299.83万港元回购15.64万股股份，每股回 购价格为18.42-19.84港元。 ...

格隆汇11月10日丨荃信生物-B(02509.HK)公告，11月10日耗资299.8万港元回购15.6万股。 ...

FF305 公司名稱： 江蘇荃信生物醫藥股份有限公司 呈交日期： 2025年11月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 確認 不適用 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02509 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括 ...

Group 1 - The company, Qianxin Biotech-B (02509.HK), announced a share buyback on November 7, spending HKD 6.071 million to repurchase 304,000 shares [1] - On November 6, the company also conducted a buyback, spending HKD 2 million to repurchase 89,000 shares [1]

Group 1 - The company, 荃信生物-B (02509), announced a share buyback on November 7, 2025, spending HKD 6.0713 million to repurchase 304,200 shares [1]